LEO 29102

Drug Profile

LEO 29102

Alternative Names: LEO-29102

Latest Information Update: 29 Aug 2015

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Acetamides; Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Psoriasis

Most Recent Events

  • 29 Aug 2015 Phase-II development for Psoriasis is ongoing in France
  • 29 Aug 2015 Phase-II development for Atopic dermatitis is ongoing in Canada, Finland and Germany
  • 30 Nov 2011 LEO Pharma completes a phase I trial in Psoriasis in France (NCT01466478)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top